The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

RNA vaccines, like COVID-19 vaccines, work better if patients are in a good mood, finds new research by Cardiff University.

Progress has been reported at the American Chemical Society conference, while the team involved has also published two papers ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

Just over half of U.S. adults (53%) say they’ve gotten neither the flu shot nor the updated COVID-19 vaccine since last ...

The Centers for Disease Control and Prevention (CDC) published 2 sets of interim estimates: a 2024-2025 COVID-19 vaccine effectiveness (VE) analysis sourced from data from the Virtual SARS-CoV-2 ...

The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug ...

Although the bivalent COVID-19 vaccine conferred moderate protection against symptomatic disease, hybrid immunity provided the strongest protection.

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

During the new Covid vaccines’ early clinical trials, they showed a 90 percent efficacy in preventing any symptoms at all. In the real world, the efficacy of early vaccines didn’t quite live ...